NASDAQ · SNWV

SANUWAVE Health, Inc.

$5.93 +$0.01 (+0.17%) 1D Market open

Key Metrics

$50.91M
Market cap
3.17×
P/E · TTM
$44.33M
Revenue · TTM
$16.05M
Net income
EPS · TTM $1.88
Dividend yield
Free cash flow $3.99M
Beta · 1Y 1.24
EBITDA · TTM $10.85M
Gross margin 76.7%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 23
    From its Jan 30 high, the share price fell 78%.

    Peak close $26.96 on Jan 30; trough close $5.92 on Jul 23. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -78%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 15
    The stock moved -39.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 15
  • Jun 16
    The stock moved -42.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 16

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$50.91M
Enterprise value$60.64M
Shares outstanding8.6M
52-wk range$5.77 – $46.59
Avg volume · 20D33.3K
Net cash −$9.73M
Book value / share$0.22
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About SANUWAVE Health, Inc.
IPO dateOct 8, 2008
Employees55

SANUWAVE Health Inc is a medical device company providing directed energy products into the wound care space.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E3.17
P/S1.15
P/FCF12.77
EV/EBITDA5.59
EV/Sales1.37
Graham №$3.01

Profitability

Gross 76.7%
Operating 22.1%
Net 36.2%
FCF 9.0%
ROE / ROIC -295.1% · —

Financial Health

Current ratio1.31
Quick ratio0.99
Debt / equity11.16
Debt / EBITDA 1.89
Net cash −$9.73M
Working capital$5.65M

Cash Flow · TTM

Operating CF $5.79M
Capex −$1.80M
Free cash flow $3.99M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

-6.1
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$3.01 vs $5.93
Trades 2.0× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings